1214 completed, 381 recruiting, 342 terminated, 248 unknown. 982 Phase 2, 760 Phase 1, 356 Not applicable, 155 Phase 3, 40 Phase 4.
Follow Kidney Neoplasms: new trials by email Literature Review of Kidney Neoplasms trials Research Report on Kidney Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial Balstilimab, Biospecimen Collection, Botensilimab - Clear Cell Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 16 | 2027-05-17 | 2026-10-21 |
| Lifileucel (TIL) Therapy After PD-1 Blockade Failure in Kidney Cancer Cyclophosphamide, Fludarabine, Aldesleukin (IL-2) - Kidney Cancers, Renal Cell Carcinoma (Kidney Cancer) | Phase 2 | Not yet recruiting | Beth Israel Deaconess Medical Center | 10 | 2027-04-26 | 2026-11-09 |
| Testing the Investigational Medication Pembrolizumab After Kidney Removal for Patients With Non-Clear Cell Renal Cell Carcinoma Biospecimen Collection, Bone Scan, Computed Tomography - Non-Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8 | Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 400 | 2027-02-10 | 2026-07-08 |
| SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma Stereotactic Body Radiation Therapy (SBRT), Anlotinib, Bemarituzumab - Locally Advanced or Metastatic Renal Cell Carcinoma | Phase 2 | Not yet recruiting | Fujian Cancer Hospital | 27 | 2027-02-01 | 2026-10-01 |
| A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors. Signatera Genome ultra-sensitive ctDNA blood test - NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer) | Not applicable | Not yet recruiting | Natera, Inc. | 920 | 2027-01-01 | 2026-10-27 |
| Study of ACC-1898 in Adult Participants With Advanced Solid Tumors ACC-1898 - Hepatocellular Carcinoma, Renal Cell Carcinoma | Phase 1 | Not yet recruiting | AccSalus Biosciences, Inc. | 40 | 2027-01-01 | 2026-10-28 |
| Pembrolizumab Plus Belzutifan With or Without Lenvatinib in Localized Renal Cell Carcinoma Neoadjuvant Pembrolizumab, Belzutifan, Lenvatinb - Renal Cell Carcinoma | Phase 2 | Not yet recruiting | Vall d'Hebron Institute of Oncology | 150 | 2027-01-01 | 2026-11-12 |
| A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC) BMS-986527, Nivolumab, Cabozantinib - Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 1 | Not yet recruiting | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 112 | 2026-12-31 | 2026-09-30 |
| Neoadjuvant Belzutifan Plus Pembrolizumab in High-Risk, Locally Advanced Clear Cell Renal Cell Carcinoma Belzutifan, Pembrolizumab - Locally Advanced Clear Cell Renal Cell Carcinoma | Phase 2 | Not yet recruiting | Peter MacCallum Cancer Centre, Australia | 30 | 2026-12-01 | 2026-10-26 |
| Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine/Cutaneous Leiomyomas, and Kidney Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Kidney Carcinoma, Advanced Renal Cell Carcinoma | Phase 1 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 18 | 2026-12-01 | 2026-08-06 |
| A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver Spread Envafolimab+Lenvatinib - Clear Cell Renal Cell Cancer (ccRCC), Liver Metastasis | Phase 2 | Not yet recruiting | Fudan University | 30 | 2026-12-01 | 2026-09-09 |
| Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 50 | 2026-12-01 | 2026-09-17 |
| Habitat Analysis of Tumor Thrombus for Vena Cava Wall Invasion in Renal Cell Carcinoma Carcinoma, Renal Cell, Inferior Vena Cava Tumor Thrombus | Not yet recruiting | Liu Zhuo | 273 | 2026-11-30 | 2026-10-28 | |
| Zanzalintinib and MO-03 for the Treatment of Metastatic Renal Cell Cancer After Progression on Immunotherapy Biospecimen Collection, Bone Scan, C. butyricum CBM 588 Probiotic Strain Capsule Formulation MO-03 - Metastatic Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8 | Phase 2 | Not yet recruiting | City of Hope Medical Center | 34 | 2026-11-28 | 2026-05-11 |
| Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors REGN13089-M404-M2980 - Advanced Solid Tumors | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 320 | 2026-11-23 | 2026-10-07 |
| Phase Ib/II Clinical Study of QLS5133 Combination Therapy in Advanced Solid Tumors QLS5133; Lenvatinib mesylate, QLS5133; QL2107; Lenvatinib mesylate, QLS5133; Bevacizumab - Clear Cell Renal Cell Carcinoma, Ovarian Cancer | Phase 1 / Phase 2 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 558 | 2026-11-15 | 2026-11-12 |
| Pucotenlimab, Lenvatinib, and SBRT Before Surgery for Localized Clear Cell Renal Cell Carcinoma Pucotenlimab, Lenvatinib, Stereotactic Body Radiotherapy - Localized Clear Cell Renal Cell Carcinoma | Phase 2 | Not yet recruiting | Sun Yat-sen University | 24 | 2026-11-10 | 2026-11-06 |
| Characterizing the Genomic Landscape of Cancer in Native American Populations (NAT-Geno) Bio-specimen Collection, Blood Draw - Prostate Cancer, Renal Cell Carcinoma (RCC) | Recruiting | University of Oklahoma | 300 | 2026-11-02 | 2026-10-13 | |
| A Study of CA9-Targeted CAR Macrophage Therapy in Advanced Clear Cell Renal Cell Carcinoma CM-BA-9 - Clear Cell Renal Cell Carcinoma | Early Phase 1 | Not yet recruiting | Liangyou Gu | 6 | 2026-11-01 | 2026-10-08 |
| Comparing Two Weight Loss Programs for the Prevention of Kidney Cancer Progression Among Patients With Small Renal Masses on Active Surveillance Intermittent Fasting, Continuous Energy Restriction (CER) - Renal Cell Carcinoma (RCC) | Not applicable | Recruiting | Roswell Park Cancer Institute | 20 | 2026-11-01 | 2026-10-16 |
Showing 20 of 2590. Sign in to see all of them.
Carcinoma, Renal Cell (1964) · Melanoma (364) · Carcinoma, Non-Small-Cell Lung (319) · Neoplasms (258) · Breast Neoplasms (255) · Neoplasm Metastasis (209) · Prostatic Neoplasms (207) · Colorectal Neoplasms (206) · Ovarian Neoplasms (201) · Wilms Tumor (199) · Urinary Bladder Neoplasms (195) · Lung Neoplasms (188) · Sarcoma (186) · Pancreatic Neoplasms (170)
Female Urogenital Diseases and Pregnancy Complications (2590) · Female Urogenital Diseases (2589) · Male Urogenital Diseases (2589) · Urogenital Diseases (2589) · Neoplasms by Site (2581) · Urologic Diseases (2577) · Kidney Diseases (2566) · Urologic Neoplasms (2561) · Urogenital Neoplasms (2560) · Neoplasms (2332) · Neoplasms by Histologic Type (2284) · Neoplasms, Glandular and Epithelial (2150) · Carcinoma (2001) · Adenocarcinoma (1982)
Nivolumab (159) · pembrolizumab (152) · Sunitinib (151) · Sorafenib (92) · Bevacizumab (86) · Everolimus (81) · Axitinib (78) · Ipilimumab (76) · cabozantinib (75) · pazopanib (69) · Cyclophosphamide (65) · aldesleukin (63) · Magnetic Resonance Spectroscopy (58) · Interleukin-2 (47) · Specimen Handling (47)
National Cancer Institute (NCI) (172) · Pfizer (79) · M.D. Anderson Cancer Center (65) · Memorial Sloan Kettering Cancer Center (48) · Bristol-Myers Squibb (38) · Novartis Pharmaceuticals (38) · Children's Oncology Group (33) · Bayer (30) · City of Hope Medical Center (25) · Merck Sharp & Dohme LLC (25) · GlaxoSmithKline (21) · RenJi Hospital (20) · Case Comprehensive Cancer Center (19) · Duke University (18) · Hoffmann-La Roche (18)
United States (1462) · France (264) · China (256) · Canada (200) · United Kingdom (198) · Italy (186) · Spain (177) · Australia (154) · Germany (149) · Netherlands (125) · South Korea (119) · Belgium (90) · Poland (82) · Japan (77) · Russia (75)
Eric Jonasch, MD (13) · Giuseppe Procopio, MD (9) · Sumanta K Pal (9) · Robert J. Motzer, MD (8)
PMID 37146227, PMID 31401903, PMID 27238653, PMID 28410911, PMID 25577718, PMID 33526329, PMID 37526095, PMID 32499241, PMID 33058158, PMID 33947608, PMID 39462179, PMID 22980441, PMID 23964934, PMID 26702763, PMID 26706103, PMID 27279544, PMID 35304832, PMID 35383907, PMID 36848607, PMID 37933882, PMID 41969229, PMID 19179301, PMID 19556464, PMID 21403127, PMID 21917625, PMID 22430088, PMID 23228299, PMID 23850254, PMID 24338498, PMID 24687826, PMID 25209242, PMID 25532471, PMID 25616710, PMID 26406150, PMID 26457466, PMID 26685869, PMID 26969090, PMID 27101285, PMID 27988238, PMID 29343557, PMID 29377755, PMID 29439857, PMID 29563634, PMID 29788981, PMID 30352550, PMID 31371341, PMID 31449468, PMID 31532520, PMID 31838007, PMID 31898992
2023 (23), P30CA033572 (21), U10CA180886 (21), 2016 (19), P30CA043703 (14), U10CA098543 (14), 2018 (13), 2019 (12), 2017 (11), 2015 (10), 2008 (9), P30CA016672 (9), 2014 (8), 2025 (8), P30CA072720 (8)